Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of t.

Business Wire • Sep 4, 2026

Tempus AI Director Nadja West Sells 3,000 Shares for $207,000

The disposition involved 3,000 shares executed at $69.00 per share, totaling $207,000 in transaction value on August 28, 2026. The shares traded were equal to 9.00% of the stake held before the filing, leaving the insider with a 0.0183% ownership interest.

The Motley Fool • Sep 2, 2026

Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

ETF Trends • Sep 2, 2026

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Benzinga • Sep 1, 2026

Top Performing Leveraged/Inverse ETFs: 08/23/2026

Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.

ETF Trends • Aug 26, 2026

What's Going On With Tempus AI Stock on Monday?

Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.

Benzinga • Aug 24, 2026

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus' growing cardiovascular portfolio, expanding the company's suite of next-generation AI products aimed at ide.

Business Wire • Aug 24, 2026

Best-Performing Leveraged ETF Areas of Last Week

These leveraged ETFs surged last week as biotech, AI, crypto and Bitcoin-linked stocks rallied despite rising Treasury yields.

Zacks Investment Research • Aug 24, 2026

Why Tempus AI Skyrocketed This Week

Tempus AI stock surged this week after Merck and Moderna published encouraging trial results for a cancer treatment. A company that Tempus AI is acquiring provided technologies that aided the development of Merck and Moderna's cancer vaccine.

The Motley Fool • Aug 23, 2026

Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know

The disposition of 133,000 shares was executed at a weighted average price of $49.61 per share, representing a total transaction value of about $6.6 million. The activity was non-discretionary, performed solely to satisfy statutory tax withholding obligations associated with the vesting of restricted stock units.

The Motley Fool • Aug 22, 2026